title: Heparin and insulin in the management of hypertriglyceridemia-associated pancreatitis: case series and literature review.
abstract: Severe hypertriglyceridemia accounts for up to 7% of all cases of acute pancreatitis. Heparin and insulin activate lipoprotein lipase (LPL), thereby reducing plasma triglyceride levels. However, the safety and efficacy of heparin and insulin in the treatment of hypertriglyceridemia-associated acute pancreatitis have not been well established yet. We successfully used heparin and insulin as first-line therapy in four consecutive patients with acute pancreatitis secondary to hypertriglyceridemia. In a literature search, we revised almost all reports published to date of patients managed successfully with this combination. Heparin and insulin appear to be a safe, effective, and inexpensive first-line therapy for hypertriglyceridemia-associated acute pancreatitis.
authors.affiliation: Division of Endocrinology and Diabetes, Medanta - The Medicity, Gurgaon, Haryana, India.
authors.forename: Mohammad Shafi
authors.initials: MS
authors.lastname: Kuchay
authors.affiliation: Division of Endocrinology and Diabetes, Medanta - The Medicity, Gurgaon, Haryana, India.
authors.forename: Khalid J
authors.initials: KJ
authors.lastname: Farooqui
authors.affiliation: Division of Endocrinology and Diabetes, Medanta - The Medicity, Gurgaon, Haryana, India.
authors.forename: Tarannum
authors.initials: T
authors.lastname: Bano
authors.affiliation: Division of Endocrinology and Diabetes, Medanta - The Medicity, Gurgaon, Haryana, India.
authors.forename: Manoj
authors.initials: M
authors.lastname: Khandelwal
authors.affiliation: Division of Endocrinology and Diabetes, Medanta - The Medicity, Gurgaon, Haryana, India.
authors.forename: Harmandeep
authors.initials: H
authors.lastname: Gill
authors.affiliation: Division of Endocrinology and Diabetes, Medanta - The Medicity, Gurgaon, Haryana, India.
authors.forename: Ambrish
authors.initials: A
authors.lastname: Mithal
mesh_terms: D000208:Acute Disease; D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D015228:Hypertriglyceridemia / Q000150:complications* / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use*; D008071:Lipoprotein Lipase / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000188:drug therapy* / Q000209:etiology*; D015203:Reproducibility of Results; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D000925:Anticoagulants; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D007328:Insulin; D014280:Triglycerides; D006493:Heparin; D008071:Lipoprotein Lipase; D011345:Fenofibrate